Brooklyn, NY -- (SBWIRE) -- 10/18/2017 -- The prevalence of various cancers has grown tremendously worldwide, with the World Health Organization expecting the annual incidence of cancer to increase to 24 million by 2035. It was estimated that the U.S. reported approximately 1.7 million new cancer cases in 2016 alone. This alarming rise has resulted in a significant unmet need for advanced and efficient medical intervention. As of now, chemotherapy, radiation therapy, and surgery are the standard approaches to treat cancer. Researchers are, however, invested in developing newer and more effective methods, including dendritic cell cancer vaccines.

Get free sample copy of the report at: https://www.qyresearchreports.com/sample/sample.php?rep_id=1206305&type=E

Dendritic cell cancer vaccines are considered to be safe and are known to enable antitumor immunity among cancer patients, even those with advanced symptoms. Research findings state that dendritic cell vaccines also present the hope of improving survival rates. These vaccines are used in cases of prostate cancer, melanoma, renal cell carcinoma, and malignant glioma, among others. The two most important trends positively impacting the dendritic cell cancer vaccines market are the growing combination of dendritic cell-based immunotherapy with other cancer therapies and the implementation of next-gen vaccines that enhance immunogenicity.

The report includes a detailed section on the manufacturing plants of dendritic cell cancer vaccines and discusses points such as distribution of manufacturing units, date of commercial production, production capacity, sources of raw materials, technology sources, and status of research and development activities.

The global market for dendritic cell cancer vaccines is studied on the basis of application, type, and region. By type, the market comprises Provenge, CreaVax, and Dendritic Cell Activated Cytokine Induced Killer Cells (DC-CIK). Based on region, the research report covers China, North America, Southeast Asia, Europe, India, and Japan.

To check available discount on this report, visit at: https://www.qyresearchreports.com/sample/sample.php?rep_id=1206305&type=D

There are several companies currently involved in the research and development of dendritic cell cancer vaccines. These include ImmunoCellular Therapeutics, Northwest Biotherapeutics, Creagene, Theravectys, Glaxo Smith Kline, Immunicum, Batavia Bioservices, DanDrit Biotech, Merck, DCPrime, Tella Incorporation, Vaxil BioTherapeutics, 3M Company, Elios Therapeutics, Medigene, Activartis, ImmunoCellular Therapeutics, Bellicum Pharmaceuticals, Kiromic, Argos Therapeutics, Dendreon Corporation, and SOTIO. The report takes into account some of the leading players in the dendritic cell cancer vaccines market and profiles them based on attributes such as product picture and specifications, regional distribution, sales, revenue, ex-factory price, and gross margin.

Table of Contents

Global Dendritic Cell Cancer Vaccine Market Professional Survey Report 2017
1 Industry Overview of Dendritic Cell Cancer Vaccine
1.1 Definition and Specifications of Dendritic Cell Cancer Vaccine
1.1.1 Definition of Dendritic Cell Cancer Vaccine
1.1.2 Specifications of Dendritic Cell Cancer Vaccine
1.2 Classification of Dendritic Cell Cancer Vaccine
1.2.1 CreaVax
1.2.2 Dendritic Cell Activated Cytokine Induced Killer Cells (DC-CIK)
1.2.3 Provenge
1.2.4 Other
1.3 Applications of Dendritic Cell Cancer Vaccine
1.3.1 Medical Research
1.3.2 Cancer Hospital
1.3.3 Other
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

2 Manufacturing Cost Structure Analysis of Dendritic Cell Cancer Vaccine
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Dendritic Cell Cancer Vaccine
2.3 Manufacturing Process Analysis of Dendritic Cell Cancer Vaccine
2.4 Industry Chain Structure of Dendritic Cell Cancer Vaccine

3 Technical Data and Manufacturing Plants Analysis of Dendritic Cell Cancer Vaccine
3.1 Capacity and Commercial Production Date of Global Dendritic Cell Cancer Vaccine Major Manufacturers in 2016
3.2 Manufacturing Plants Distribution of Global Dendritic Cell Cancer Vaccine Major Manufacturers in 2016
3.3 R&D Status and Technology Source of Global Dendritic Cell Cancer Vaccine Major Manufacturers in 2016
3.4 Raw Materials Sources Analysis of Global Dendritic Cell Cancer Vaccine Major Manufacturers in 2016

4 Global Dendritic Cell Cancer Vaccine Overall Market Overview
4.1 2012-2017E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 2012-2017E Global Dendritic Cell Cancer Vaccine Capacity and Growth Rate Analysis
4.2.2 2016 Dendritic Cell Cancer Vaccine Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 2012-2017E Global Dendritic Cell Cancer Vaccine Sales and Growth Rate Analysis
4.3.2 2016 Dendritic Cell Cancer Vaccine Sales Analysis (Company Segment)

About QYReseachReports.com
QYReseachReports.com delivers the latest strategic market intelligence to build a successful business footprint in China. Our syndicated and customized research reports provide companies with vital background information of the market and in-depth analysis on the Chinese trade and investment framework, which directly affects their business operations. Reports from QYReseachReports.com feature valuable recommendations on how to navigate in the extremely unpredictable yet highly attractive Chinese market.

Contact US:
Brooklyn, NY 11230
United States
Toll Free: 866-997-4948 (USA-CANADA)
Tel: +1-518-618-1030
Web: http://www.qyresearchreports.com
Email: sales@qyresearchreports.com